REVVITY (RVTY) Company Report

Revvity saw a $60 million Q3-to-Q4 uplift in FY2025 driven by life sciences instrumentation demand, the Genomics England contract ($2 million in Q3 rising to $7 million in Q4), strong ex-China immunodiagnostics, partially offset by a $5–7 million FX drag on absolute revenue.
Life sciences reagents achieved low-single digit organic growth amid pharma biotech normalization and modest U.S. academia/government shutdown impact, with Revvity indicating share gains in a depressed market.
The Signals software business outperformed, growing over 20% in FY2025 (APV up ~19%), bolstered by customer engagement, renewals, and upcoming launches such as BioDesign and AI-driven drug discovery tools.
EUROIMMUN immunodiagnostics ex-China grew mid- to high-single digits, especially in the U.S., while China diagnostics faces DRG reform noise; Revvity targets a low-teens China revenue mix and local innovation for stability.
For 2026, Revvity guides 2–3% revenue growth and 28% EBITDA margins, and plans to pursue disciplined M&A alongside opportunistic share buybacks.

Dec 2, 2025, 2:00 PM

Transcript

Revvity presents at Citi Annual Global Healthcare Conference 2025

RVTY

Guidance Update

M&A

Product Launch

Revvity reported an expected Q3 to Q4 FY25 life sciences uplift of $60 million, driven by increased instrument activity, a Genomics England contract that rose from $2 million to $7 million, and strong ex-China immunodiagnostic performance.
BioLegend accounts for ~50 % of reagents revenue; modest academic/government impact from the US shutdown is offset by recovering pharma/biotech demand as market uncertainty subsides and M&A activity normalizes over the next 1–2 quarters.
The Signals software segment achieved ~19 % APV growth in FY25—outpacing the 9–11 % long-range target—through continued investment, customer engagement, and new product launches (Clinical, Synergy, BioDesign) alongside the ACD/Labs acquisition.
For FY26, Revvity guides 2–3 % organic revenue growth and 28 % operating margins, assuming stable market conditions, calendarized China diagnostics headwinds, and ongoing margin initiatives; capital allocation will remain opportunistic with selective M&A and share buybacks.

Dec 2, 2025, 2:00 PM

Transcript

Revvity outlines FY25 performance drivers and FY26 guidance at Citi Healthcare Conference

RVTY

Guidance Update

Life sciences instrumentation saw a $60 million sequential uplift from Q3 to Q4 FY25, driven by the Genomics England contract (Q3: $2 m; Q4: $7 m), sustained scientific instrument orders, and ex-China immunodiagnostics, partly offset by a $5–7 million FX headwind.
Reagents (incl. BioLegend) delivered low single-digit organic growth in a depressed market; pharma/biotech demand is normalizing over the next 1–2 quarters despite academic/government shutdown impacts.
Signals software outperformed targets, growing >20% each quarter in FY25 and increasing annualized portfolio value by ~19%; upcoming launches include BioDesign in Q1 FY26 and AI-driven platforms in late 2026/2027.
China faces short-term policy volatility (DRG, VBP, Sunshine Act), but Revvity expects China to stabilize at low-teens of total revenue in FY26, with ex-China markets sustaining mid-single-digit growth.
Preliminary FY26 guidance: 2–3% revenue growth and 28% operating margin, reflecting a calendarized China diagnostics drag and ongoing margin initiatives (restructuring, sourcing, integration).

Dec 2, 2025, 2:00 PM

Transcript

Revvity discusses Q3 performance and 2026 outlook at Jefferies London Healthcare Conference

RVTY

Guidance Update

Revvity delivered 1% organic growth in Q3 2025, with flat Life Sciences and low-single-digit Diagnostics growth driven by newborn screening, offsetting weaker reagents performance.
Reagents revenue was $750 million, split ~2/3 pharma/biotech (up low-single-digits YTD) and ~1/3 academic/government (down low-single-digits YTD).
September–October order intake in high-content screening (25% of instrumentation portfolio; ASPs $0.5–1.5 million) underpins an expected return to instrumentation growth in Q4 after multiple years of declines.
Software revenue is up 25% YTD, with ~33% SaaS penetration (targeting 65–70% over 3–5 years) and underlying low-double-digit APV growth; mid-single-digit organic growth is forecast for 2026 despite RevRec timing.
For 2026, Revvity projects 2–3% organic growth and a 28% operating margin (vs. 27.2% in 2025), driven by China footprint actions, facility consolidations, and M&A synergies.

Nov 18, 2025, 2:00 PM

Transcript

Revvity discusses Q3 performance and FY26 outlook

RVTY

Guidance Update

Revenue Acceleration/Inflection

Revvity delivered 1% organic growth in 3Q25, with Life Sciences flat and Diagnostics up low single digits.
The reagents business (~$750 M revenue) is ~2/3 pharma and ~1/3 academic/government, with low single‐digit growth YTD; GMP capacity went live mid-2024 and is expected to ramp over the next 3+ years.
Instrumentation bookings, led by high-content screening (ASPs $0.5–1.5 M, 3–4 month lead time), picked up in Sept–Oct, underpinning an expected return to growth in 4Q25.
Software is up 25% YTD, with a 9–11% long-range growth target; new product launches and expansion into material sciences support upside, and SaaS now represents ~33% of the portfolio (65–70% entitlement).
Operating margin for FY25 is ~27.2%; for FY26, Revvity targets 28% on 2–3% organic growth via China footprint optimization, rooftop consolidations, and M&A synergies.

Nov 18, 2025, 2:00 PM

Transcript

Revvity outlines business outlook at Jefferies London Healthcare Conference 2025

RVTY

Guidance Update

Revvity delivered 1% organic growth in 3Q, with Life Sciences flat and Diagnostics up low single digits.
The software segment is up ~25% year-to-date, with normalized underlying growth expected to be low double digits in 2026, driven by strong retention, broader customer adoption, and upcoming product launches.
Newborn screening grew mid- to high single digits, outpacing birth-rate declines, fueled by geographic expansion, menu adoption in existing programs, and addition of new assays.
High-content screening instrumentation orders from large pharma increased in September–October, supporting a return to growth in Q4 after a multi-year downturn.
Management forecasts 28% operating margin on 2–3% organic growth for next year, aided by footprint consolidations, M&A synergies, and the anticipated reset of China diagnostics to low-single-digit growth post-anniversary of recent policy changes.

Nov 18, 2025, 2:00 PM

Transcript

Revvity acquires ACD/Labs to expand life sciences software

RVTY

M&A

Revvity announced it will acquire ACD/Labs, a scientific software provider, with the deal expected to close in late Q4 2025
The acquisition aims to deepen Revvity Signals’ presence in research informatics and create a unified SaaS environment across molecular design, analytical science, and manufacturing quality control
Management projects the deal will support 2%–4% organic growth and deliver an adjusted EPS of $4.90–$5, aided by increased share buybacks
Despite recent declines in revenue growth and operating margins, Revvity maintains strong gross margins and liquidity

Nov 10, 2025, 1:28 PM

Morningstar

Revvity outlines growth and strategic priorities at UBS Global Healthcare Conference 2025

RVTY

Guidance Update

Share Buyback

Product Launch

In Q3, Revvity achieved organic growth in line with expectations, with software up 20%, newborn screening high single digits, U.S. immunodiagnostics mid-teens, and 90% free cash flow conversion.
Reagents e-commerce penetration increased from 25% to ~45% since early 2024, targeting 65–70% long-term.
Signals software’s APV is growing in the low teens; SaaS accounts for ~33% of the portfolio (entitlement 65–70% by 2030), and a large molecule solution will launch early 2026.
The 2026 framework targets 2–3% organic growth, life sciences and diagnostics in low-single digits, a 28% operating margin baseline, and ~$900 million in share repurchases.

Nov 10, 2025, 1:00 PM

Transcript

Revvity presents at UBS Global Healthcare Conference 2025

RVTY

Product Launch

Share Buyback

Guidance Update

Solid Q3 performance: organic growth and operating margins in line with expectations; 90% free cash flow conversion; software up 20%, newborn screening grew high single digits, US immunodiagnostics grew mid-teens.
Reagents and GMP: e-commerce penetration nearly doubled to ~45%, targeting >65-70% of sales through the platform; GMP facility completed end of 2023, expected to drive meaningful revenue over the next 3-5 years.
Signals software evolution: organic growth timing driven by renewals with APV growth in low double digits; 1/3 of portfolio sold as SaaS (entitlement ~65-70%); launching large molecule preclinical workflow in early 2026; ACD/Labs acquisition ($70 M for $20 M revenue) EPS neutral 2026, accretive thereafter.
Diagnostics momentum: US immunodiagnostics mid-teens growth via FDA menu expansion and automation; newborn screening up high single digits driven by geographic and panel expansion; TB automation gaining traction with 20 medium-throughput systems placed; genomics partnerships (e.g., Sanofi Type 1 diabetes) supporting growth.
2026 outlook and capital allocation: targeting 2-3% organic growth (life sciences low single digits; DX low-mid single digits); returning to 28% operating margin baseline via channel and supply chain optimization; ~$900 M share repurchased YTD; disciplined M&A focus with ~2.6% cost of debt and leverage in the low-3s target.

Nov 10, 2025, 1:00 PM

Transcript

Revvity outlines growth drivers and 2026 framework at UBS Global Healthcare Conference 2025

RVTY

Guidance Update

Share Buyback

M&A

Revvity delivered a solid Q3 with organic growth and operating margins in line with expectations, ~90% free cash flow conversion, software revenue up 20%, newborn screening up high single digits, and U.S. immunodiagnostics up mid-teens.
Strategic initiatives include boosting reagents e-commerce penetration to ~45% of sales, completing a GMP facility build-out (end-2023) with commercial traction expected over the next few years, and deploying AI enhancements across instruments, DX interpretation, and internal processes.
The company reaffirmed its 2026 framework targeting 2–3% organic growth, with life sciences low-single-digit growth (instruments flat, reagents modest), software mid-single digits, DX low-to-mid single digits, and a baseline ~28% operating margin.
Capital allocation remains opportunistic: repurchased ~$900 M of shares vs. a $250 M plan, completed a $70 M tuck-in acquisition of ACD/Labs, and maintains a $3 B investment-grade debt base at ~2.6% average rate.

Nov 10, 2025, 1:00 PM

Transcript

Earnings Transcripts

Quarterly earnings call transcripts for REVVITY.

Q3 2025

Oct 27, 2025

→

Q2 2025

Jul 28, 2025

→

Q1 2025

Apr 28, 2025

→

View All Transcripts

Ask Fintool AI Agent

Get instant answers from SEC filings, earnings calls & more

What did Prahlad Singh say about margins?What are REVVITY's strategic priorities?How is REVVITY positioned vs competitors?How did REVVITY do last quarter?

REVVITY (RVTY)

Analyst Earnings Quarterly Reports

Q3 2025

Q2 2025

Q1 2025

Q4 2024

Executives

Prahlad Singh

Anita Gonzales

Joel Goldberg

Maxwell Krakowiak

Miriame Victor

Tajinder Vohra

Board Members

Alexis Michas

Frank Witney

Michael Klobuchar

Michel Vounatsos

Michelle McMurry-Heath

Pascale Witz

Peter Barrett

Samuel Chapin

Sophie Vandebroek

Analyst Coverage

Patrick Donnelly

Vijay Kumar

Daniel Brennan

Luke Sergott

Michael Ryskin

Puneet Souda

Matthew Sykes

Andrew Cooper

Catherine Schulte

Dan Arias

Daniel Arias

Daniel Leonard

Dan Leonard

Doug Schenkel

Tycho Peterson

Brandon Couillard

Catherine Ramsey

Douglas Schenkel

Jack Meehan

Rachel Vatnsdal

Subbu Nambi

Latest news

Earnings Transcripts

Q3 2025

Q2 2025

Q1 2025

Ask Fintool AI Agent